Kura Oncology spins out diabetes pipeline with $50M and Lilly

Kura Oncology spins out its diabetes pipeline into new biotech Caspian Therapeutics, backed by $50M including from Eli Lilly. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo…

Kyle LaHucik · 2026-09-09

Kura Oncology, the maker of the leukemia menin inhibitor Komzifti, is spinning out its diabetes R&D to a new company that has attracted the attention of the leading pharma in the metabolic ...

Source: Endpoints News